Whole-exome data (N = 88 samples) generated mutational profiles and candidate neoantigens and were analysed along with RNA-Nanostring 545-gene expression (N = 96 samples) and stromal TILs (N = 105 samples) from 35 patients with HER2-negative breast cancer (Fig. 1a). The gene discussed is ERBB2; the disease is breast cancer.